Hematopoietic stem cells for treatment of hematologic malignancies

The purpose of this clinical application was to determine the immunosuppressive conditions required for effective HLA-haploidentical bone marrow transplantation, initiated to treat hematologic malignancies. High post-transplant doses of cyclosporine A decreased the incidence of severe chronic graft-versus-host disease (GvHD) in HLA-mismatched transplantations.